We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

20 hedge funds and large institutions have $7.34M invested in vTv Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

19% more capital invested

Capital invested by funds: $6.15M → $7.34M (+$1.19M)

7.99% more ownership

Funds ownership: 14.33% → 22.32% (+8%)

5% more funds holding

Funds holding: 19 → 20 (+1)

Holders
20
Holders Change
+1
Holders Change %
+5.26%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$282K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$171K
4
BlackRock
BlackRock
New York
+$60.6K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$4.91K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$216K
2
UBS Group
UBS Group
Switzerland
-$55K
3
JP Morgan Chase
JP Morgan Chase
New York
-$35
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$18
5
TWP
Triad Wealth Partners
Kansas
-$18
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$2.81M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.4M +$2.96M +178,200 New
BBA
3
Baker Bros. Advisors
New York
$1.32M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$560K +$282K +17,000 +69%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$139K +$171K +10,307 New
BlackRock
6
BlackRock
New York
$64.4K +$60.6K +3,653 +333%
UBS Group
7
UBS Group
Switzerland
$11.7K -$55K -3,314 -79%
Morgan Stanley
8
Morgan Stanley
New York
$11.4K – – –
PCMC
9
Planning Capital Management Corporation
Pennsylvania
$8.48K – – –
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$4K +$4.91K +296 New
TRCT
11
Tower Research Capital (TRC)
New York
$3.65K +$4.46K +269 New
Osaic Holdings
12
Osaic Holdings
Arizona
$2.41K +$133 +8 +5%
SFCL
13
Strengthening Families & Communities LLC
Massachusetts
$2.35K – – –
AWM
14
Activest Wealth Management
Florida
$678 – – –
PA
15
Parallel Advisors
California
$515 – – –
PS
16
Planned Solutions
California
$339 +$415 +25 New
CPG
17
Cornerstone Planning Group
New Jersey
$265 – – –
SS
18
Sunbelt Securities
Texas
$203 – – –
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
$121 – – –
Bank of America
20
Bank of America
North Carolina
$109 – – –
Millennium Management
21
Millennium Management
New York
– -$216K -12,256 Closed
JP Morgan Chase
22
JP Morgan Chase
New York
– -$35 -2 Closed
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
– -$18 -1 Closed
TWP
24
Triad Wealth Partners
Kansas
– -$18 -1 Closed

VTVT Hedge Fund Activity: Q3 2024 in Review

20 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2024, worth a combined $7.34M — up 19% from $6.15M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VTVT positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $2.96M. The largest seller was Millennium Management, exiting entirely with an estimated $216K sold.

  • 20 institutional investors held vTv Therapeutics (VTVT) as of Q3 2024, up from 19 in Q2 2024.
  • Funds reported $7.34M of vTv Therapeutics stock for Q3 2024, up 19% quarter-over-quarter.
  • 5 funds opened new vTv Therapeutics positions in Q3 2024 and 4 closed out, a net change of +1 holder.
  • The largest vTv Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $2.96M added.
  • The largest vTv Therapeutics seller in Q3 2024 was Millennium Management, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2024.